Loading…
Statin therapy in hepatitis: a systematic review and meta-analysis of 9 studies with 195,602 participants
Abstract Background Conflicting data suggest that statins could cause hepatitis in certain group of patients, while improving prognosis in patients affected by some chronic liver diseases. Therefore, we aimed to quantify the potential protective role of statins on some main liver-related health outc...
Saved in:
| Published in: | European heart journal 2021-10, Vol.42 (Supplement_1) |
|---|---|
| Main Authors: | , , , , , , , |
| Format: | Article |
| Language: | English |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | |
|---|---|
| cites | |
| container_end_page | |
| container_issue | Supplement_1 |
| container_start_page | |
| container_title | European heart journal |
| container_volume | 42 |
| creator | Vahedian-Azimi, A Shojaie, S Banach, M Heidari, F Cicero, A F G Fetrat, M K Jamialahmadi, T Sahabkar, A F G |
| description | Abstract
Background
Conflicting data suggest that statins could cause hepatitis in certain group of patients, while improving prognosis in patients affected by some chronic liver diseases. Therefore, we aimed to quantify the potential protective role of statins on some main liver-related health outcomes in clinical studies on patients affected by hepatitis.
Methods
We applied fixed-effects or random-effects meta-analyses with inverse variance weighting to calculate pooled estimates and confidence intervals (95% confidence intervals [CI]). We calculated the odds ratios (OR) and 95% CI for the targets of mortality and hepatocellular carcinoma, fibrosis, and cirrhosis.
Results
Nine studies (N: 195,602 patients) reported data on mortality of patients affected by chronic viral hepatitis, six studies (N: 72,960) reported data on the risk to develop hepatocellular carcinoma, two studies on fibrosis progression (N: 9678) and two studies (N: 85,205) on cirrhosis development. Statins reduce the risk to develop hepatocarcinoma (OR (95% CI) = 0.47 (0.28, 0.81), p=0.005) (Figure 1), liver fibrosis (OR (95% CI) = 0.55 (0.34, 0.87), p |
| doi_str_mv | 10.1093/eurheartj/ehab724.2949 |
| format | article |
| fullrecord | <record><control><sourceid>oup_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1093_eurheartj_ehab724_2949</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><oup_id>10.1093/eurheartj/ehab724.2949</oup_id><sourcerecordid>10.1093/eurheartj/ehab724.2949</sourcerecordid><originalsourceid>FETCH-LOGICAL-c899-c4fb6f55b8129f3c477bdbb464ecd2ef6b23bfdb40ce0da56fee137ab4dd12a03</originalsourceid><addsrcrecordid>eNqNkM9KAzEQh4MoWKuvIHkAt02y2WzjTYr_oODBHrwtk2TCprTbJUkt-_ZuqXj2NDM_-GaGj5B7zmac6XKOh9gixLyZYwumFnImtNQXZMIrIQqtZHVJJozrqlBq8XVNblLaMMYWiqsJCZ8ZcuhobjFCP9CxbbEfoxzSIwWahpRxN86WRvwOeKTQObrDDAV0sB1SSHTvqaYpH1zARI8ht3Q89qCYoP34VrChhy6nW3LlYZvw7rdOyfrleb18K1Yfr-_Lp1VhF1oXVnqjfFWZBRfal1bWtXHGSCXROoFeGVEa74xkFpmDSnlEXtZgpHNcACunRJ3X2rhPKaJv-hh2EIeGs-bkq_nz1fz6ak6-RpCfwf2h_y_zAyVAdgM</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Statin therapy in hepatitis: a systematic review and meta-analysis of 9 studies with 195,602 participants</title><source>Oxford Academic</source><creator>Vahedian-Azimi, A ; Shojaie, S ; Banach, M ; Heidari, F ; Cicero, A F G ; Fetrat, M K ; Jamialahmadi, T ; Sahabkar, A F G</creator><creatorcontrib>Vahedian-Azimi, A ; Shojaie, S ; Banach, M ; Heidari, F ; Cicero, A F G ; Fetrat, M K ; Jamialahmadi, T ; Sahabkar, A F G</creatorcontrib><description>Abstract
Background
Conflicting data suggest that statins could cause hepatitis in certain group of patients, while improving prognosis in patients affected by some chronic liver diseases. Therefore, we aimed to quantify the potential protective role of statins on some main liver-related health outcomes in clinical studies on patients affected by hepatitis.
Methods
We applied fixed-effects or random-effects meta-analyses with inverse variance weighting to calculate pooled estimates and confidence intervals (95% confidence intervals [CI]). We calculated the odds ratios (OR) and 95% CI for the targets of mortality and hepatocellular carcinoma, fibrosis, and cirrhosis.
Results
Nine studies (N: 195,602 patients) reported data on mortality of patients affected by chronic viral hepatitis, six studies (N: 72,960) reported data on the risk to develop hepatocellular carcinoma, two studies on fibrosis progression (N: 9678) and two studies (N: 85,205) on cirrhosis development. Statins reduce the risk to develop hepatocarcinoma (OR (95% CI) = 0.47 (0.28, 0.81), p=0.005) (Figure 1), liver fibrosis (OR (95% CI) = 0.55 (0.34, 0.87), p<0.001), and cirrhosis (OR (95% CI) = 0.59 (0.55, 0.62), p<0.0001). There was also no significant link between statin therapy and alanine (Figure 2) and aspartate aminotransferases levels. Moreover, statin therapy is associated with a significant reduction in mortality but only in studies longer than 3 years (OR (95% CI) = 0.38 (0.17, 0.85), p=0.006).
Conclusion
Long-term treatment with statins seems to be safe in patients affected by hepatitis, while significantly improving their prognosis. Extensive education should be continued in order to avoid discontinuing statin therapy in patients with liver diseases.
Funding Acknowledgement
Type of funding sources: None.
Figure 1Figure 2</description><identifier>ISSN: 0195-668X</identifier><identifier>EISSN: 1522-9645</identifier><identifier>DOI: 10.1093/eurheartj/ehab724.2949</identifier><language>eng</language><publisher>Oxford University Press</publisher><ispartof>European heart journal, 2021-10, Vol.42 (Supplement_1)</ispartof><rights>Published on behalf of the European Society of Cardiology. All rights reserved. © The Author(s) 2021. For permissions, please email: journals.permissions@oup.com. 2021</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>315,786,790,27957,27958</link.rule.ids></links><search><creatorcontrib>Vahedian-Azimi, A</creatorcontrib><creatorcontrib>Shojaie, S</creatorcontrib><creatorcontrib>Banach, M</creatorcontrib><creatorcontrib>Heidari, F</creatorcontrib><creatorcontrib>Cicero, A F G</creatorcontrib><creatorcontrib>Fetrat, M K</creatorcontrib><creatorcontrib>Jamialahmadi, T</creatorcontrib><creatorcontrib>Sahabkar, A F G</creatorcontrib><title>Statin therapy in hepatitis: a systematic review and meta-analysis of 9 studies with 195,602 participants</title><title>European heart journal</title><description>Abstract
Background
Conflicting data suggest that statins could cause hepatitis in certain group of patients, while improving prognosis in patients affected by some chronic liver diseases. Therefore, we aimed to quantify the potential protective role of statins on some main liver-related health outcomes in clinical studies on patients affected by hepatitis.
Methods
We applied fixed-effects or random-effects meta-analyses with inverse variance weighting to calculate pooled estimates and confidence intervals (95% confidence intervals [CI]). We calculated the odds ratios (OR) and 95% CI for the targets of mortality and hepatocellular carcinoma, fibrosis, and cirrhosis.
Results
Nine studies (N: 195,602 patients) reported data on mortality of patients affected by chronic viral hepatitis, six studies (N: 72,960) reported data on the risk to develop hepatocellular carcinoma, two studies on fibrosis progression (N: 9678) and two studies (N: 85,205) on cirrhosis development. Statins reduce the risk to develop hepatocarcinoma (OR (95% CI) = 0.47 (0.28, 0.81), p=0.005) (Figure 1), liver fibrosis (OR (95% CI) = 0.55 (0.34, 0.87), p<0.001), and cirrhosis (OR (95% CI) = 0.59 (0.55, 0.62), p<0.0001). There was also no significant link between statin therapy and alanine (Figure 2) and aspartate aminotransferases levels. Moreover, statin therapy is associated with a significant reduction in mortality but only in studies longer than 3 years (OR (95% CI) = 0.38 (0.17, 0.85), p=0.006).
Conclusion
Long-term treatment with statins seems to be safe in patients affected by hepatitis, while significantly improving their prognosis. Extensive education should be continued in order to avoid discontinuing statin therapy in patients with liver diseases.
Funding Acknowledgement
Type of funding sources: None.
Figure 1Figure 2</description><issn>0195-668X</issn><issn>1522-9645</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><recordid>eNqNkM9KAzEQh4MoWKuvIHkAt02y2WzjTYr_oODBHrwtk2TCprTbJUkt-_ZuqXj2NDM_-GaGj5B7zmac6XKOh9gixLyZYwumFnImtNQXZMIrIQqtZHVJJozrqlBq8XVNblLaMMYWiqsJCZ8ZcuhobjFCP9CxbbEfoxzSIwWahpRxN86WRvwOeKTQObrDDAV0sB1SSHTvqaYpH1zARI8ht3Q89qCYoP34VrChhy6nW3LlYZvw7rdOyfrleb18K1Yfr-_Lp1VhF1oXVnqjfFWZBRfal1bWtXHGSCXROoFeGVEa74xkFpmDSnlEXtZgpHNcACunRJ3X2rhPKaJv-hh2EIeGs-bkq_nz1fz6ak6-RpCfwf2h_y_zAyVAdgM</recordid><startdate>20211012</startdate><enddate>20211012</enddate><creator>Vahedian-Azimi, A</creator><creator>Shojaie, S</creator><creator>Banach, M</creator><creator>Heidari, F</creator><creator>Cicero, A F G</creator><creator>Fetrat, M K</creator><creator>Jamialahmadi, T</creator><creator>Sahabkar, A F G</creator><general>Oxford University Press</general><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>20211012</creationdate><title>Statin therapy in hepatitis: a systematic review and meta-analysis of 9 studies with 195,602 participants</title><author>Vahedian-Azimi, A ; Shojaie, S ; Banach, M ; Heidari, F ; Cicero, A F G ; Fetrat, M K ; Jamialahmadi, T ; Sahabkar, A F G</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c899-c4fb6f55b8129f3c477bdbb464ecd2ef6b23bfdb40ce0da56fee137ab4dd12a03</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Vahedian-Azimi, A</creatorcontrib><creatorcontrib>Shojaie, S</creatorcontrib><creatorcontrib>Banach, M</creatorcontrib><creatorcontrib>Heidari, F</creatorcontrib><creatorcontrib>Cicero, A F G</creatorcontrib><creatorcontrib>Fetrat, M K</creatorcontrib><creatorcontrib>Jamialahmadi, T</creatorcontrib><creatorcontrib>Sahabkar, A F G</creatorcontrib><collection>CrossRef</collection><jtitle>European heart journal</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Vahedian-Azimi, A</au><au>Shojaie, S</au><au>Banach, M</au><au>Heidari, F</au><au>Cicero, A F G</au><au>Fetrat, M K</au><au>Jamialahmadi, T</au><au>Sahabkar, A F G</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Statin therapy in hepatitis: a systematic review and meta-analysis of 9 studies with 195,602 participants</atitle><jtitle>European heart journal</jtitle><date>2021-10-12</date><risdate>2021</risdate><volume>42</volume><issue>Supplement_1</issue><issn>0195-668X</issn><eissn>1522-9645</eissn><abstract>Abstract
Background
Conflicting data suggest that statins could cause hepatitis in certain group of patients, while improving prognosis in patients affected by some chronic liver diseases. Therefore, we aimed to quantify the potential protective role of statins on some main liver-related health outcomes in clinical studies on patients affected by hepatitis.
Methods
We applied fixed-effects or random-effects meta-analyses with inverse variance weighting to calculate pooled estimates and confidence intervals (95% confidence intervals [CI]). We calculated the odds ratios (OR) and 95% CI for the targets of mortality and hepatocellular carcinoma, fibrosis, and cirrhosis.
Results
Nine studies (N: 195,602 patients) reported data on mortality of patients affected by chronic viral hepatitis, six studies (N: 72,960) reported data on the risk to develop hepatocellular carcinoma, two studies on fibrosis progression (N: 9678) and two studies (N: 85,205) on cirrhosis development. Statins reduce the risk to develop hepatocarcinoma (OR (95% CI) = 0.47 (0.28, 0.81), p=0.005) (Figure 1), liver fibrosis (OR (95% CI) = 0.55 (0.34, 0.87), p<0.001), and cirrhosis (OR (95% CI) = 0.59 (0.55, 0.62), p<0.0001). There was also no significant link between statin therapy and alanine (Figure 2) and aspartate aminotransferases levels. Moreover, statin therapy is associated with a significant reduction in mortality but only in studies longer than 3 years (OR (95% CI) = 0.38 (0.17, 0.85), p=0.006).
Conclusion
Long-term treatment with statins seems to be safe in patients affected by hepatitis, while significantly improving their prognosis. Extensive education should be continued in order to avoid discontinuing statin therapy in patients with liver diseases.
Funding Acknowledgement
Type of funding sources: None.
Figure 1Figure 2</abstract><pub>Oxford University Press</pub><doi>10.1093/eurheartj/ehab724.2949</doi></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0195-668X |
| ispartof | European heart journal, 2021-10, Vol.42 (Supplement_1) |
| issn | 0195-668X 1522-9645 |
| language | eng |
| recordid | cdi_crossref_primary_10_1093_eurheartj_ehab724_2949 |
| source | Oxford Academic |
| title | Statin therapy in hepatitis: a systematic review and meta-analysis of 9 studies with 195,602 participants |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-09-22T02%3A30%3A39IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-oup_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Statin%20therapy%20in%20hepatitis:%20a%20systematic%20review%20and%20meta-analysis%20of%209%20studies%20with%20195,602%20participants&rft.jtitle=European%20heart%20journal&rft.au=Vahedian-Azimi,%20A&rft.date=2021-10-12&rft.volume=42&rft.issue=Supplement_1&rft.issn=0195-668X&rft.eissn=1522-9645&rft_id=info:doi/10.1093/eurheartj/ehab724.2949&rft_dat=%3Coup_cross%3E10.1093/eurheartj/ehab724.2949%3C/oup_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c899-c4fb6f55b8129f3c477bdbb464ecd2ef6b23bfdb40ce0da56fee137ab4dd12a03%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/&rft_oup_id=10.1093/eurheartj/ehab724.2949&rfr_iscdi=true |